CureVac’s COVID-19 vaccine (CVnCoV)
Withdrawn from rolling review
This medicine has been withdrawn from evaluation under rolling review
COVID-19 mRNA vaccine
MedicineHumanWithdrawn from rolling review
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
- Rolling review
- Withdrawal of application
Overview
EMA has ended the rolling review of CVnCoV, CureVac’s COVID-19 vaccine, after the company informed the Agency that it was withdrawing from the process.
The rolling review started on 12 February 2021; the company withdrew on 11 October 2021.
Key facts
- Name of medicine
- CureVac’s COVID-19 vaccine (CVnCoV)
- International non-proprietary name (INN) or common name
- COVID-19 mRNA vaccine
- EMA product number
- EMEA/H/C/005845
- Developer
- CureVac AG
- Start of rolling review
- 12/02/2021
- Withdrawal from rolling review
- 11/10/2021
This page was last updated on